Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.85 |
---|---|
High | 2.85 |
Low | 2.53 |
Bid | 2.56 |
Offer | 2.59 |
Previous close | 2.82 |
Average volume | 49.76k |
---|---|
Shares outstanding | 2.60m |
Free float | 2.33m |
P/E (TTM) | -- |
Market cap | 7.33m USD |
EPS (TTM) | -24.59 USD |
Data delayed at least 15 minutes, as of Oct 04 2024 20:04 BST.
More ▼
Announcements
- Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
- Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
- Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
- Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
- Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
- Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Vaccinex Reports 2023 Financial Results and Provides Corporate Update
- Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
- Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
- Vaccinex, Inc. Announces Reverse Stock Split
More ▼